Indication-specific authorization

Prior authorization: distinguish formulation and indication during request. Indication-specific authorization is required — document whether the request is for zoledronic acid 5 mg (Reclast) or 4 mg (Zometa/generic) and the covered indication (e.g., postmenopausal osteoporosis, osteoporosis in men, glucocorticoid‑induced osteoporosis, Paget’s disease for 5 mg; bone metastases, hypercalcemia of malignancy, multiple myeloma, ADT‑associated osteoporosis, Langerhans cell histiocytosis, systemic mastocytosis for 4 mg). PA requests should specify dose (4 mg vs 5 mg) since approved uses and dosing/retreatment intervals differ by formulation.

• Ensure the requested HCPCS (e.g., J3489) and dose/unit match the indication.
• For Paget’s disease include documentation of serum alkaline phosphatase ≥2x age‑adjusted ULN or symptomatic disease.

Indication and menopausal‑status requirement

When adjuvant or oncology‑adjacent uses are requested (for example, adjuvant therapy in breast cancer or prevention of AI‑associated bone loss), document menopausal status where relevant. Postmenopausal status must be clearly stated; if menopause is surgically or medically induced, document timing and labs (LH, FSH, estradiol) as noted in specialty guidance.

• Postmenopausal = ≥12 months amenorrhea or biochemical confirmation when required (women ≤60 with prior hysterectomy: LH/FSH/estradiol in postmenopausal range).
• For adjuvant bisphosphonate requests, record whether therapy is intended for bone density maintenance, fracture risk reduction, or distant metastasis risk reduction.

Prior authorization recommended for off‑label or specialty uses

Prior authorization recommended for off‑label, investigational, or specialty uses beyond core FDA or compendial oncology indications. Requests for uses listed as experimental/investigational (e.g., Charcot neuroarthropathy, osteogenesis imperfecta pediatric off‑label, ankylosing spondylitis) should include supporting peer‑reviewed evidence and rationale; absence of adequate evidence may lead to denial.

• Concurrent use of multiple ZA formulations or another bisphosphonate is considered experimental — provide justification if requested.
• Refer to the CPB list of experimental/unproven indications when submitting requests.

Indication and duration justification

Authorization must justify indication and intended duration of therapy. For osteoporosis and glucocorticoid‑associated osteoporosis include numeric criteria (history of fragility fracture, pretreatment T‑score ≤ −2.5, or osteopenia with high FRAX probability). For Paget’s disease document alkaline phosphatase thresholds and re‑treatment rationale. For hypercalcemia of malignancy provide corrected serum calcium and prior therapies.

• Osteoporosis: include BMD (T‑score), fracture history, and FRAX when applicable.
• Glucocorticoid‑associated osteoporosis: document prednisone‑equivalent dose (≥2.5 mg/day for ≥3 months per policy) and planned duration; note FDA language requiring expected glucocorticoid use ≥12 months for Reclast approval context.
• Hypercalcemia: provide albumin‑corrected calcium value (cCa ≥12 mg/dL), prior interventions, and renal function.

Glucocorticoid‑associated osteoporosis (approval context)

Reclast (zoledronic acid 5 mg) approval context: indicate if request is for treatment or prevention of osteoporosis including glucocorticoid‑induced osteoporosis. For steroid‑induced osteoporosis cite the FDA approval context (expected glucocorticoid use for ≥12 months) and supporting trial data when relevant.

• Document planned infusion schedule (annual for treatment; every 2 years permitted for prevention per label) and concurrent calcium/vitamin D supplementation.
• For glucocorticoid cases, document current/planned steroid dose and expected duration.

Prior authorization — plan verification

Prior authorization: none stated in some policy chunks, but providers must also refer to plan provisions. The CPB describes clinical rules; actual PA requirements depend on the member’s benefit plan. Verify plan‑level PA rules and the Clinical Policy Bulletin for implementation.

• Clinical Policy Bulletins are partial descriptions of plan benefits and do not guarantee coverage; check contract language.
• Contact plan administration or use the payer portal to confirm if PA is required for the specific member/plan.

Evidence‑supported vs limited/experimental indications

Use of zoledronic acid should be limited to indications with evidence of benefit. Evidence‑supported indications include hypercalcemia of malignancy, bone metastases/multiple myeloma for prevention of SREs, and approved osteoporosis indications. Indications with limited, conflicting, or negative evidence (e.g., routine adjuvant use in early breast cancer per some trials, Charcot neuroarthropathy) require careful documentation of rationale and anticipated benefit.

• For adjuvant breast cancer, record menopausal status and risk stratification — benefit in adjuvant bisphosphonate trials is largely in postmenopausal women.
• Charcot neuroarthropathy: trials suggest lack of benefit or possible harm — routine use is not recommended.

Pre‑ and post‑infusion patient preparation

Pre‑ and post‑infusion patient preparation must be documented. Obtain baseline renal function (serum creatinine/CrCl) prior to each dose, ensure adequate hydration (especially in hypercalcemia and Paget’s patients), and confirm calcium and vitamin D repletion to reduce hypocalcemia risk. Dental examination and preventive dentistry should be completed prior to therapy when used for cancer‑related bone disease.

• Do not administer Reclast if CrCl <35 mL/min or with acute renal impairment — document latest serum creatinine/CrCl.
• For Paget’s disease: document hydration plan, orders for calcium 1500 mg elemental and vitamin D 800 IU daily, and patient counseling on hypocalcemia symptoms.

Therapy duration and re‑evaluation

Therapy duration and re‑evaluation: periodic reassessment of continued therapy is required. For postmenopausal osteoporosis consider discontinuation for low‑risk patients after 3–5 years and re‑evaluate fracture risk; for oncology and hypercalcemia indications, follow disease response and standard oncology intervals.

• Document clinical benefit (disease stability/improvement) for continuation requests.
• For Paget’s and hypercalcemia, document biochemical response (e.g., alkaline phosphatase normalization, corrected calcium) to support re‑treatment.

Concurrent use with other bisphosphonates

Concurrent use of zoledronic acid 4 mg with zoledronic acid 5 mg, or concurrent use of another IV bisphosphonate with ZA, is considered experimental/investigational and is not recommended. If such therapy is requested, include clinical justification and supporting evidence.

• Policy lists concurrent use with other ZA formulations or another bisphosphonate as investigational.
• PA requests for overlapping bisphosphonate regimens will be subject to review and possible denial.

Agent selection guidance and step therapy considerations

Agent selection guidance: the policy does not mandate step therapy between agents. Selection between zoledronic acid and alternatives (e.g., pamidronate, denosumab) should be clinically justified. Document prior trials, contraindications, or intolerance to alternatives when relevant.

• Where relevant, document trial or contraindication to alternative IV bisphosphonate (step therapy considerations vs pamidronate) — also note comparative effectiveness limitations.
• For ADT or other oncology prevention settings, note whether denosumab vs ZA selection is based on clinical factors or cost.

Prior bisphosphonate exposure

Prior bisphosphonate exposure: include history of prior IV or oral bisphosphonate use (e.g., prior pamidronate in pediatric/OI cases) as this may inform dosing decisions and safety monitoring.

• For pediatric OI or switch from pamidronate to ZA, document prior dosing history and response.
• If prior serious bisphosphonate adverse effects occurred (e.g., osteonecrosis of the jaw), provide risk‑benefit discussion.

Comparative effectiveness context

Comparative effectiveness context: limited head‑to‑head data exist for some indications. When choosing ZA over alternatives, document the comparative rationale (efficacy, dosing frequency, infusion time, renal considerations, and trial data) to support medical necessity.

• Hypercalcemia trials show higher response rates and faster infusion time for ZA vs pamidronate — document if this influenced agent choice.
• For multiple myeloma and bone metastases, note that ZA and pamidronate have similar effectiveness; denosumab may be superior in some advanced settings.

Step therapy — none stated in policy summaries

Step therapy: none explicitly required by the evidence summaries in this section, but local plan policies may impose step edits. Check member benefit and PA systems for any plan‑level step therapy rules before submitting.

• If plan-level step therapy is present, document completion of required trials or provide clinical rationale for bypassing steps.

Documentation requirements and FRAX guidance

Documentation and supplemental guidance: ensure PA submissions include BMD measurements, fracture outcomes, laboratory values (e.g., serum creatinine, albumin, corrected calcium, alkaline phosphatase), FRAX calculation when applicable, supplement prescriptions (calcium/vitamin D), dental exam documentation for oncology bone‑modifying therapy, and policy review dates for auditability.

• FRAX guidance: high FRAX = 10‑year major osteoporotic fracture risk ≥20% or hip fracture risk ≥3%; adjust score multipliers for higher steroid doses as specified.
• Include policy history and review dates (effective 2002‑03‑12; last review 02/01/2024; next review 12/12/2024) for reference in complex cases.

Clinical Policy Bulletin — scope and verification

Clinical Policy Bulletins and scope: CPBs are partial descriptions of plan benefits and do not guarantee coverage. Treating providers are responsible for clinical decisions; verify member benefit terms and use the CPB to support but not replace plan‑level determinations.

• CPB updates may change criteria — rely on the current published CPB and payer portal for the operative rules.
• Contact payer if there is discrepancy between CPB language and contract terms.